Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis

Cancer Biol Ther. 2008 Sep;7(9):1386-7. doi: 10.4161/cbt.7.9.6757. Epub 2008 Sep 6.

Authors

Cindy H Chau¹, Weixin Wang, William D Figg

Affiliation

¹ Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

PMID: 18769127
DOI: 10.4161/cbt.7.9.6757

No abstract available

Publication types

Comment

MeSH terms

Carrier Proteins / antagonists & inhibitors*
Cyclophosphamide / therapeutic use*
Humans
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
Neovascularization, Pathologic / genetics*
Phosphatidylinositol 3-Kinases / metabolism
Phosphotransferases (Alcohol Group Acceptor) / antagonists & inhibitors*
Proto-Oncogene Proteins c-akt / metabolism
Stomach Neoplasms / blood supply*
Stomach Neoplasms / genetics
Stomach Neoplasms / metabolism*
TOR Serine-Threonine Kinases
Vascular Endothelial Growth Factor A / biosynthesis

Substances

Carrier Proteins
HIF1A protein, human
Hypoxia-Inducible Factor 1, alpha Subunit
Vascular Endothelial Growth Factor A
Cyclophosphamide
Phosphotransferases (Alcohol Group Acceptor)
MTOR protein, human
Proto-Oncogene Proteins c-akt
TOR Serine-Threonine Kinases